Michael Platten

List of Publications by Year
in descending order

281 papers	27,685 citations	9264 74 h-index	6471 157 g-index
289 all docs	289 docs citations	289 times ranked	30704 citing authors

#	Article	IF	Citations
1	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clinical Cancer Research, 2022, 28, 585-593.	7.0	18
2	Association of iron rim lesions with brain and cervical cord volume in relapsing multiple sclerosis. European Radiology, 2022, 32, 2012-2022.	4.5	19
3	Long-term dynamics of multiple sclerosis iron rim lesions. Multiple Sclerosis and Related Disorders, 2022, 57, 103340.	2.0	24
4	T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas. Clinical Cancer Research, 2022, 28, 378-389.	7.0	11
5	Automatic deep learning multicontrast corpus callosum segmentation in multiple sclerosis. Journal of Neuroimaging, 2022, 32, 459-470.	2.0	5
6	Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV. International Journal of Molecular Sciences, 2022, 23, 1029.	4.1	1
7	The current landscape of immunotherapy for pediatric brain tumors. Nature Cancer, 2022, 3, 11-24.	13.2	21
8	Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature, 2022, 603, 321-327.	27.8	343
9	Consistency of the â€œcentral vein signâ€•in chronic multiple sclerosis lesions. Multiple Sclerosis and Related Disorders, 2022, 58, 103530.	2.0	1
10	Hippocampal subfield involvement in patients with transient global amnesia. Journal of Neuroimaging, 2022, 32, 264-267.	2.0	2
11	Cortical and white matter lesion topology influences focal corpus callosum atrophy in multiple sclerosis. Journal of Neuroimaging, 2022, 32, 471-479.	2.0	3
12	Treatment standards for direct oral anticoagulants in patients with acute ischemic stroke and non-valvular atrial fibrillation: A survey among German stroke units. PLoS ONE, 2022, 17, e0264122.	2.5	5
13	Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101. Neuro-Oncology Practice, 2022, 9, 310-316.	1.6	7
14	MRI predictors for the conversion from contrast-enhancing to iron rim multiple sclerosis lesions. Journal of Neurology, 2022, , 1.	3.6	6
15	The remains of the day: neuropsychological findings in postacute transient global amnesia. Journal of Neurology, 2022, 269, 4764-4771.	3.6	3
16	How mutant isocitrate dehydrogenase orchestrates immune cells. Neuro-Oncology, 2022, 24, 210-212.	1.2	0
17	Neuroimaging phenotypes of CSF1Râ€related leukoencephalopathy: Systematic review, metaâ€analysis, and imaging recommendations. Journal of Internal Medicine, 2022, 291, 269-282.	6.0	14
18	AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas. Neurological Research and Practice, 2022, 4, .	2.0	13

#	Article	IF	Citations
19	Patient-Derived Tumor Organoids for Guidance of Personalized Drug Therapies in Recurrent Glioblastoma. International Journal of Molecular Sciences, 2022, 23, 6572.	4.1	9
20	Spatial distribution of multiple sclerosis iron rim lesions and their impact on disability. Multiple Sclerosis and Related Disorders, 2022, 64, 103967.	2.0	6
21	Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions. Multiple Sclerosis Journal, 2022, 28, 2294-2298.	3.0	7
22	Decreased utilization of mental health emergency service during the COVID-19 pandemic. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 377-379.	3.2	99
23	Venous Diameter Changes in Chronic Active Multiple Sclerosis Lesions. Journal of Neuroimaging, 2021, 31, 394-400.	2.0	6
24	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nature Reviews Clinical Oncology, 2021, 18, 170-186.	27.6	826
25	Activity-regulated cytoskeleton-associated protein/activity-regulated gene 3.1 (Arc/Arg3.1) enhances dendritic cell vaccination in experimental melanoma. OncoImmunology, 2021, 10, 1920739.	4.6	2
26	Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110396.	3.5	86
27	A Set of Cell Lines Derived from a Genetic Murine Glioblastoma Model Recapitulates Molecular and Morphological Characteristics of Human Tumors. Cancers, 2021, 13, 230.	3.7	13
28	Neisseria meningitidis serogroup W(P1.5-2) sepsis presenting with myopericarditis in an elderly previously healthy male. IDCases, 2021, 25, e01238.	0.9	2
29	Deep Learning Corpus Callosum Segmentation as a Neurodegenerative Marker in Multiple Sclerosis. Journal of Neuroimaging, 2021, 31, 493-500.	2.0	13
30	Hypoxia Routes Tryptophan Homeostasis Towards Increased Tryptamine Production. Frontiers in Immunology, 2021, 12, 590532.	4.8	6
31	Central retinal artery occlusion as a neuroâ€ophthalmological emergency: the need to raise public awareness. European Journal of Neurology, 2021, 28, 2111-2114.	3.3	13
32	A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature, 2021, 592, 463-468.	27.8	232
33	MRI topography of lesions related to internuclear ophthalmoplegia in patients with multiple sclerosis or ischemic stroke. Journal of Neuroimaging, 2021, 31, 471-474.	2.0	4
34	Diffusely appearing white matter in multiple sclerosis: Insights from sodium (23Na) MRI. Multiple Sclerosis and Related Disorders, 2021, 49, 102752.	2.0	10
35	COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system. Nature Communications, 2021, 12, 2417.	12.8	75
36	Impaired semantic memory during acute transient global amnesia. Journal of Neuropsychology, 2021, , .	1.4	2

#	Article	IF	Citations
37	Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas. Nature Cancer, 2021, 2, 723-740.	13.2	110
38	Characterization of chronic active multiple sclerosis lesions with sodium (²³Na) magnetic resonance imagingâ€"preliminary observations. European Journal of Neurology, 2021, 28, 2392-2395.	3.3	8
39	Quantitative MRI texture analysis in chronic active multiple sclerosis lesions. Magnetic Resonance Imaging, 2021, 79, 97-102.	1.8	5
40	Sex-related differences in stressful events precipitating transient global amnesia â€“ A retrospective observational study. Journal of the Neurological Sciences, 2021, 425, 117464.	0.6	6
41	Tryptophan metabolism in brain tumors â€" IDO and beyond. Current Opinion in Immunology, 2021, 70, 57-66.	5.5	30
42	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. , 2021, 9, e002459.		41
43	Intrathecal activation of CD8 ⁺ memory T cells in IgG4â€related disease of the brain parenchyma. EMBO Molecular Medicine, 2021, 13, e13953.	6.9	6
44	Comparative evaluation of T cell receptors in experimental glioma-draining lymph nodes. Neuro-Oncology Advances, 2021, 3, vdab147.	0.7	1
45	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	12.8	237
46	Tryptophan metabolism is inversely regulated in the tumor and blood of patients with glioblastoma. Theranostics, 2021, 11, 9217-9233.	10.0	16
47	Unique challenges for glioblastoma immunotherapyâ€"discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro-Oncology, 2021, 23, 356-375.	1.2	59
48	Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. The Lancet Digital Health, 2021, 3, e784-e794.	12.3	52
49	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. Journal of Clinical Oncology, 2021, 39, 3839-3852.	1.6	93
50	Mapping the Multiple Myeloma T Cell Landscape By Immunotherapeutic Perturbation Reveals Mechanism and Determinants of Response to Bispecific T Cell Engagers. Blood, 2021, 138, 731-731.	1.4	3
51	Genetically Modified Cellular Therapies for Malignant Gliomas. International Journal of Molecular Sciences, 2021, 22, 12810.	4.1	9
52	Driving mesenchymal transition in glioblastoma. Neuro-Oncology, 2020, 22, 1-2.	1.2	36
53	The therapeutic potential of targeting tryptophan catabolism in cancer. British Journal of Cancer, 2020, 122, 30-44.	6.4	159
54	Autoimmune diseases and immunosuppressive therapy in relation to the risk of glioma. Cancer Medicine, 2020, 9, 1263-1275.	2.8	11

#	Article	IF	Citations
55	MRIâ€Based Manual versus Automated Corpus Callosum Volumetric Measurements in Multiple Sclerosis. Journal of Neuroimaging, 2020, 30, 198-204.	2.0	6
56	cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma. Journal of Neuro-Oncology, 2020, 146, 9-23.	2.9	12
57	Hepatocyte-intrinsic type I interferon signaling reprograms metabolism and reveals a novel compensatory mechanism of the tryptophan-kynurenine pathway in viral hepatitis. PLoS Pathogens, 2020, 16, e1008973.	4.7	6
58	Large-scale characterization of the microvascular geometry in development and disease by tissue clearing and quantitative ultramicroscopy. Journal of Cerebral Blood Flow and Metabolism, 2020, 41, 0271678X2096185.	4.3	10
59	Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. Cancer Medicine, 2020, 9, 8373-8385.	2.8	19
60	Changes in Demographic and Diagnostic Spectra of Patients with Neurological Symptoms Presenting to an Emergency Department During the COVID-19 Pandemic: A Retrospective Cohort Study . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2221-2227.	2.2	4
61	Decreased admissions and change in arrival mode in patients with cerebrovascular events during the first surge of the COVID-19 pandemic. Neurological Research and Practice, 2020, 2, 47.	2.0	1
62	Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. Radiology, 2020, 297, 164-175.	7.3	19
63	Investigation of the â€œcentral vein signâ€•in infratentorial multiple sclerosis lesions. Multiple Sclerosis and Related Disorders, 2020, 45, 102409.	2.0	8
64	Susceptibilityâ€Weighted 3T MRI of the Swallow Tail Sign in Multiple Sclerosis: A Case Control Study. Journal of Neuroimaging, 2020, 30, 766-768.	2.0	3
65	Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBPÎ². Frontiers in Immunology, 2020, 11, 657.	4.8	24
66	Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. Neuro-Oncology, 2020, 22, 1667-1676.	1.2	9
67	Machine Learning and Multiparametric Brain MRI to Differentiate Hereditary Diffuse Leukodystrophy with Spheroids from Multiple Sclerosis. Journal of Neuroimaging, 2020, 30, 674-682.	2.0	12
68	Diffusion-weighted MRI in transient global amnesia and its diagnostic implications. Neurology, 2020, 95, e206-e212.	1.1	46
69	INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies. BMC Cancer, 2020, 20, 523.	2.6	24
70	Acute Stroke in Times of the COVID-19 Pandemic. Stroke, 2020, 51, 2224-2227.	2.0	154
71	LAPTM5â€“CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance. Frontiers in Oncology, 2020, 10, 747.	2.8	13
72	Comparing Expert and Non-Expert Assessment of Patients Presenting with Neurological Symptoms to the Emergency Department: A Retrospective Observational Study . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 447-456.	2.2	4

#	Article	IF	Citations
73	Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma. Neuro-Oncology Advances, 2020, 2, vdz060.	0.7	8
74	Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. Neuro-Oncology, 2020, 22, 1162-1172.	1.2	42
75	Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. Nature Communications, 2020, 11, 931.	12.8	112
76	Monitoring innate immune cell dynamics in the glioma microenvironment by magnetic resonance imaging and multiphoton microscopy (MR-MPM). Theranostics, 2020, 10, 1873-1883.	10.0	30
77	Validation of Rapid Magnetic Resonance Myelin Imaging in Multiple Sclerosis. Annals of Neurology, 2020, 87, 710-724.	5.3	42
78	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology, 2020, 22, 1073-1113.	1.2	543
79	Single-Cell High-Throughput Technologies in Cerebrospinal Fluid Research and Diagnostics. Frontiers in Immunology, 2019, 10, 1302.	4.8	12
80	Dietary tryptophan links encephalogenicity of autoreactive T cells with gut microbial ecology. Nature Communications, 2019, 10, 4877.	12.8	69
81	Uncompleted emergency department care and discharge against medical advice in patients with neurological complaints: a chart review. BMC Emergency Medicine, 2019, 19, 52.	1.9	12
82	Characterization of Contrast-Enhancing and Non-contrast-enhancing Multiple Sclerosis Lesions Using Susceptibility-Weighted Imaging. Frontiers in Neurology, 2019, 10, 1082.	2.4	21
83	Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. Acta Neuropathologica Communications, 2019, 7, 163.	5.2	37
84	Interaction between the heart and the brain in transient global amnesia. Journal of Neurology, 2019, 266, 3048-3057.	3.6	13
85	Temporal evolution of acute multiple sclerosis lesions on serial sodium (23Na) MRI. Multiple Sclerosis and Related Disorders, 2019, 29, 48-54.	2.0	22
86	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Molecular and Cellular Proteomics, 2019, 18, 1255-1268.	3.8	45
87	Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. Neurology, 2019, 92, e2754-e2763.	1.1	9
88	Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. Neuro-Oncology, 2019, 21, 837-853.	1.2	66
89	Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. Lancet Oncology, The, 2019, 20, 728-740.	10.7	271
90	How to integrate immunotherapy into standard of care in glioblastoma. Neuro-Oncology, 2019, 21, 699-700.	1.2	4

#	Article	IF	Citations
91	Susceptibilityâ€weighted imaging in malignant melanoma brain metastasis. Journal of Magnetic Resonance Imaging, 2019, 50, 1251-1259.	3.4	11
92	Practice-changing developments in neuro-oncology: embracing heterogeneity. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641982768.	3.5	1
93	Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nature Reviews Drug Discovery, 2019, 18, 379-401.	46.4	805
94	TCR validation toward gene therapy for cancer. Methods in Enzymology, 2019, 629, 419-441.	1.0	7
95	High-throughput discovery of cancer-targeting TCRs. Methods in Enzymology, 2019, 629, 401-417.	1.0	6
96	Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature, 2019, 565, 240-245.	27.8	637
97	Acute Corticonuclear Tract Ischemic Stroke with Isolated Central Facial Palsy. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 495-498.	1.6	2
98	Diffusion-weighted imaging of the dentate nucleus after repeated application of gadolinium-based contrast agents in multiple sclerosis. Magnetic Resonance Imaging, 2019, 58, 1-5.	1.8	17
99	MRI of Iron Oxide Nanoparticles and Myeloperoxidase Activity Links Inflammation to Brain Edema in Experimental Cerebral Malaria. Radiology, 2019, 290, 359-367.	7.3	11
100	Brain Atrophy in Natalizumabâ€treated Patients with Multiple Sclerosis: A 5â€year Retrospective Study. Journal of Neuroimaging, 2019, 29, 190-192.	2.0	7
101	N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. Neuro-Oncology, 2019, 21, 95-105.	1.2	100
102	Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib. Clinical Cancer Research, 2019, 25, 253-265.	7.0	42
103	Abstract 4454: Identification of BAY-218, a potent and selective small-molecule AhR inhibitor, as a new modality to counteract tumor immunosuppression. Cancer Research, 2019, 79, 4454-4454.	0.9	11
104	INFORM2 exploratory multinational phase I/II combination study of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies: INFORM2 NivEnt.. Journal of Clinical Oncology, 2019, 37, TPS10065-TPS10065.	1.6	5
105	Fulminant Cytotoxic Edema in a Patient with Pneumococcal Meningoencephalitis. Journal of Clinical		

#	Article	IF	Citations
109	Oral DNA vaccination targeting VEGFR-2 combined with anti-PD-L1 avelumab in patients with progressive glioblastoma, a phase I/II study: NCT03750071.. Journal of Clinical Oncology, 2019, 37, TPS2076-TPS2076.	1.6	0
110	Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on the methylation subgroup.. Journal of Clinical Oncology, 2019, 37, 2013-2013.	1.6	0
111	Abstract 1288: Blocking tumor-associated immune suppression with BAY-218, a novel, selective aryl hydrocarbon receptor (AhR) inhibitor. Cancer Research, 2019, 79, 1288-1288.	0.9	8
112	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathologica, 2018, 136, 153-166.	7.7	298
113	Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Nonâ€“Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 777-787.	5.6	129
114	Off-label use of IV t-PA in patients with intracranial neoplasm and cavernoma. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628561775342.	3.5	8
115	Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma. Molecular Cancer Research, 2018, 16, 767-776.	3.4	25
116	Spatiotemporal evolution of venous narrowing in acute MS lesions. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e440.	6.0	10
117	Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylationâ€”the NCT Neuro Master Match (N2M2) pilot study. Neuro-Oncology, 2018, 20, 826-837.	1.2	32
118	Fourier Transform Infrared Microscopy Enables Guidance of Automated Mass Spectrometry Imaging to Predefined Tissue Morphologies. Scientific Reports, 2018, 8, 313.	3.3	37
119	Synergy of vaccination and agonist OX40 treatmentâ€”toward a mechanism-driven combination of glioma immunotherapy. Neuro-Oncology, 2018, 20, 4-5.	1.2	4
120	Vaccine Strategies in Gliomas. Current Treatment Options in Neurology, 2018, 20, 11.	1.8	12
121	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872
122	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathologica, 2018, 136, 273-291.	7.7	190
123	Concepts for Immunotherapies in Gliomas. Seminars in Neurology, 2018, 38, 062-072.	1.4	26
124	Glioblastoma in elderly patients: solid conclusions built on shifting sand?. Neuro-Oncology, 2018, 20, 174-183.	1.2	33
125	Lack of T1 hyperintensity in the dentate nucleus after 15 administrations of a macrocyclic contrast agent in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 324-326.	1.9	7
126	Radiologic progression of glioblastoma under therapyâ€”an exploratory analysis of AVAglio. Neuro-Oncology, 2018, 20, 557-566.	1.2	24

#	Article	IF	Citations
127	Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. Neuro-Oncology, 2018, 20, 367-379.	1.2	79
128	Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas. Current Opinion in Oncology, 2018, 30, 368-374.	2.4	18
129	Upregulation of tryptophanyl-tRNA synthethase adapts human cancer cells to nutritional stress caused by tryptophan degradation. OncoImmunology, 2018, 7, e1486353.	4.6	62
130	Nonmeasurable Speckled Contrast-Enhancing Lesions Appearing During Course of Disease Are Associated With IDH Mutation in High-Grade Astrocytoma Patients. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1472-1480.	0.8	5
131	T cells engineered to home in on brain cancer. Nature, 2018, 561, 319-320.	27.8	5
132	Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathologica, 2018, 136, 181-210.	7.7	308
133	Understanding and Treating Glioblastoma. Neurologic Clinics, 2018, 36, 485-499.	1.8	18
134	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Molecular and Cellular Proteomics, 2018, 17, 2132-2145.	3.8	41
135	Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nature Medicine, 2018, 24, 1192-1203.	30.7	359
136	Correlated MRI and Ultramicroscopy (MR-UM) of Brain Tumors Reveals Vast Heterogeneity of Tumor Infiltration and Neoangiogenesis in Preclinical Models and Human Disease. Frontiers in Neuroscience, 2018, 12, 1004.	2.8	16
137	A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).. Journal of Clinical Oncology, 2018, 36, 2001-2001.	1.6	21
138	VXM01 phase I study in patients with progressive glioblastoma: Final results.. Journal of Clinical Oncology, 2018, 36, 2017-2017.	1.6	87
139	Towards a molecular algorithm predicting glioma treatment response and resistance: A biomarker analysis and path to real time profiling in N2M2.. Journal of Clinical Oncology, 2018, 36, 12090-12090.	1.6	0
140	Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer. OncoImmunology, 2017, 6, e1274477.	4.6	30
141	Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis. Scientific Reports, 2017, 7, 41271.	3.3	53
142	Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathologica, 2017, 133, 629-644.	7.7	146
143	Synovial Fibroblasts Selectively Suppress Th1 Cell Responses through IDO1-Mediated Tryptophan Catabolism. Journal of Immunology, 2017, 198, 3109-3117.	0.8	27
144	Suppression of Th1 differentiation by tryptophan supplementation in vivo. Amino Acids, 2017, 49, 1169-1175.	2.7	23

#	Article	IF	Citations
145	Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nature Reviews Neurology, 2017, 13, 363-374.	10.1	125
146	Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients. Journal of Neurology, 2017, 264, 341-349.	3.6	18
147	Structural Basis for Aryl Hydrocarbon Receptor-Mediated Gene Activation. Structure, 2017, 25, 1025-1033.e3.	3.3	95
148	Tweety-Homolog 1 Drives Brain Colonization of Gliomas. Journal of Neuroscience, 2017, 37, 6837-6850.	3.6	129
149	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncology, The, 2017, 18, 682-694.	10.7	586
150	Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. Acta Neuropathologica, 2017, 133, 325-327.	7.7	12
151	The promises of immunotherapy in gliomas. Current Opinion in Neurology, 2017, 30, 650-658.	3.6	16
152	EGFRvIII vaccine in glioblastomaâ€"InACT-IVe or not ReACTive enough?. Neuro-Oncology, 2017, 19, 1425-1426.	1.2	20
153	Fully automated joint space width measurement and digital X-ray radiogrammetry in early RA. RMD Open, 2017, 3, e000369.	3.8	8
154	Lomustine and Bevacizumab in Progressive Glioblastoma. New England Journal of Medicine, 2017, 377, 1954-1963.	27.0	670
155	K27M-mutant histone-3 as a novel target for glioma immunotherapy. OncoImmunology, 2017, 6, e1328340.	4.6	74
156	Iron Induces Anti-tumor Activity in Tumor-Associated Macrophages. Frontiers in Immunology, 2017, 8, 1479.	4.8	121
157	HIV-Associated Cerebellar Dysfunction and Improvement with Aminopyridine Therapy: A Case Report. Case Reports in Neurology, 2017, 9, 121-126.	0.7	7
158	VXM01 phase I study in patients with resectable progression of a glioblastoma.. Journal of Clinical Oncology, 2017, 35, 2061-2061.	1.6	4
159	Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy. Oncotarget, 2016, 7, 56713-56725.	1.8	36
160	Tryptophanâ€2,3â€dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptorâ€4. Journal of Neurochemistry, 2016, 136, 1142-1154.	3.9	48
161	Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trialâ€"study protocol. BMJ Open, 2016, 6, e010956.	1.9	46
162	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology, 2016, 18, now133.	1.2	130

#	Article	IF	Citations
163	Neurological sequelae of cancer immunotherapies and targeted therapies. Lancet Oncology, The, 2016, 17, e529-e541.	10.7	71
164	Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). Clinical Cancer Research, 2016, 22, 4797-4806.	7.0	105
165	General control non-derepressible 2 (GCN2) in T cells controls disease progression of autoimmune neuroinflammation. Journal of Neuroimmunology, 2016, 297, 117-126.	2.3	21
166	Highlights in Central Nervous System Tumors. JAMA Oncology, 2016, 2, 1535.	7.1	1
167	Concepts in glioma immunotherapy. Cancer Immunology, Immunotherapy, 2016, 65, 1269-1275.	4.2	52
168	Normal mast cell numbers in the tissues of AhRâ€deficient mice. Experimental Dermatology, 2016, 25, 62-63.	2.9	6
169	Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma. Journal of Neuro-Oncology, 2016, 129, 533-539.	2.9	5
170	The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas. OncoImmunology, 2016, 5, e1240858.	4.6	51
171	In vivo nanoparticle imaging of innate immune cells can serve as a marker of disease severity in a model of multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13227-13232.	7.1	87
172	Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis. Journal of Translational Medicine, 2016, 14, 99.	4.4	8
173	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathologica, 2016, 131, 903-910.	7.7	203
174	Current status and future directions of anti-angiogenic therapy for gliomas. Neuro-Oncology, 2016, 18, 315-328.	1.2	61
175	Abstract 2654: GAPVAC-101 phase I trial: First data of an innovative actively personalized peptide vaccination trial in patients with newly diagnosed glioblastoma. , 2016, , .		1
176	EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma.. Journal of Clinical Oncology, 2016, 34, 2001-2001.	1.6	46
177	Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.. Journal of Clinical Oncology, 2016, 34, 2019-2019.	1.6	14
178	A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).. Journal of Clinical Oncology, 2016, 34, TPS2082-TPS2082.	1.6	6
179	Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (NÂ²MÂ²).. Journal of Clinical Oncology, 2016, 34, TPS2084-TPS2084.	1.6	4
180	Adding Papillomacular Bundle Measurements to Standard Optical Coherence Tomography Does Not Increase Sensitivity to Detect Prior Optic Neuritis in Patients with Multiple Sclerosis. PLoS ONE, 2016, 11, e0155322.	2.5	4

#	Article	IF	Citations
181	Prognostic relevance of miRNA-155 methylation in anaplastic glioma. Oncotarget, 2016, 7, 82028-82045.	1.8	21
182	Correlated magnetic resonance imaging and ultramicroscopy (MR-UM) is a tool kit to assess the dynamics of glioma angiogenesis. ELife, 2016, 5, e11712.	6.0	40
183	Effect of Glioma N-Myc downstream regulated gene 1 (NDRG1) on the tumor microenvironment.. Journal of Clinical Oncology, 2016, 34, 11587-11587.	1.6	0
184	Accumulation of an Endogenous Tryptophan-Derived Metabolite in Colorectal and Breast Cancers. PLoS ONE, 2015, 10, e0122046.	2.5	76
185	IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathologica, 2015, 129, 867-873.	7.7	272
186	Cancer immunotherapy: exploiting neoepitopes. Cell Research, 2015, 25, 887-888.	12.0	25
187	Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathologica, 2015, 130, 407-417.	7.7	237
188	Tregs in gliomas - the jury is still out. Neuro-Oncology, 2015, 17, 769-770.	1.2	4
189	MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clinical Cancer Research, 2015, 21, 2057-2064.	7.0	264
190	Brain tumour cells interconnect to a functional and resistant network. Nature, 2015, 528, 93-98.	27.8	787
191	Toxicity of teriflunomide in aryl hydrocarbon receptor deficient mice. Biochemical Pharmacology, 2015, 98, 484-492.	4.4	8
192	ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an â€œintegratedâ€•diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathologica, 2015, 129, 133-146.	7.7	378
193	Treatment of Anaplastic Glioma. Cancer Treatment and Research, 2015, 163, 89-101.	0.5	18
194	Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. Glia, 2015, 63, 78-90.	4.9	51
195	Proximity ligation assay evaluates IDH1R132H presentation in gliomas. Journal of Clinical Investigation, 2015, 125, 593-606.	8.2	35
196	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.. Journal of Clinical Oncology, 2015, 33, 2001-2001.	1.6	9
197	Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma. Oncotarget, 2015, 6, 31050-31068.	1.8	52
198	Mutant IDH1: An immunotherapeutic target in tumors. OncoImmunology, 2014, 3, e974392.	4.6	23

#	Article	IF	Citations
199	Trial watch: IDO inhibitors in cancer therapy. OncoImmunology, 2014, 3, e957994.	4.6	223
200	Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro-Oncology, 2014, 16, 1630-1638.	1.2	77
201	Good maths is needed to understand CMV data in glioblastoma. International Journal of Cancer, 2014, 134, 2991-2992.	5.1	9
202	mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 409-414.	7.1	152
203	CMV infection and glioma, a highly controversial concept struggling in the clinical arena. Neuro-Oncology, 2014, 16, 332-333.	1.2	25
204	Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma. Journal of Neuro-Oncology, 2014, 117, 85-92.	2.9	11
205	Dietary tryptophan is required for CNS infiltration of encephalitogenic T cells. Journal of Neuroimmunology, 2014, 275, 156.	2.3	1
206	In situ proximity ligation assay to evaluate presentation of a mutated CD4 epitope in human glioma tissue. Journal of Neuroimmunology, 2014, 275, 35.	2.3	0
207	Tryptophan-2,3-dioxygenase in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2014, 275, 65.	2.3	0
208	Mutant IDH1R132H bears a mutation-specific CD4 T cell epitope suitable for vaccination of human CNS tumors. Journal of Neuroimmunology, 2014, 275, 39.	2.3	0
209	Inhibition of kynurenine 3-monooxygenase in EAE. Journal of Neuroimmunology, 2014, 275, 127.	2.3	0
210	Impaired remission from autoimmune neuroinflammation upon T cell-specific knockout of the stress kinase GCN2. Journal of Neuroimmunology, 2014, 275, 174.	2.3	0
211	UV irradiation-mediated systemic immune suppression through AHR signalling. Journal of Neuroimmunology, 2014, 275, 128-129.	2.3	0
212	A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma. Clinical Cancer Research, 2014, 20, 6304-6313.	7.0	111
213	Challenging cytomegalovirus data in glioblastoma. Neuro-Oncology, 2014, 16, 165-165.	1.2	10
214	Understanding and Targeting Alkylator Resistance in Glioblastoma. Cancer Discovery, 2014, 4, 1120-1122.	9.4	35
215	Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity?. Journal of Neurochemistry, 2014, 131, 251-264.	3.9	47
216	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathologica, 2014, 128, 561-571.	7.7	176

#	Article	IF	Citations
217	Microenvironmental Clues for Glioma Immunotherapy. Current Neurology and Neuroscience Reports, 2014, 14, 440.	4.2	51
218	A vaccine targeting mutant IDH1 induces antitumour immunity. Nature, 2014, 512, 324-327.	27.8	613
219	Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature, 2014, 511, 184-190.	27.8	574
220	MGMT testingâ€"the challenges for biomarker-based glioma treatment. Nature Reviews Neurology, 2014, 10, 372-385.	10.1	454
221	Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors. Frontiers in Immunology, 2014, 5, 673.	4.8	284
222	Radiation therapy and concurrent plus adjuvant temsirolimus (CCI-779) versus chemoirradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter.. Journal of Clinical Oncology, 2014, 32, 2003-2003.	1.6	13
223	Final results of APG101_CD_002: APG101 plus reirradiation versus reirradiation in the treatment of patients with progressive glioblastoma.. Journal of Clinical Oncology, 2014, 32, 2006-2006.	1.6	2
224	MGMT promoter methylation as a prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: First results from the randomized phase II DIRECTOR trial.. Journal of Clinical Oncology, 2014, 32, 2015-2015.	1.6	6
225	Determining the glioma CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide methylation data in the biomarker cohort of the NOA-04 trial.. Journal of Clinical Oncology, 2014, 32, 2017-2017.	1.6	3
226	Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget, 2014, 5, 1038-1051.	1.8	248
227	ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathologica, 2013, 126, 443-451.	7.7	304
228	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathologica, 2013, 126, 907-915.	7.7	254
229	The Endogenous Tryptophan Metabolite and NAD+ Precursor Quinolinic Acid Confers Resistance of Gliomas to Oxidative Stress. Cancer Research, 2013, 73, 3225-3234.	0.9	126
230	Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma. Journal of Neuroimmunology, 2013, 265, 106-116.	2.3	81
231	Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology, 2013, 81, 1515-1522.	1.1	211
232	Aryl hydrocarbon receptor (AhR) regulation of inflammation and cancer. Toxicology Letters, 2013, 221, S29.	0.8	0
233	Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro-Oncology, 2013, 15, 1017-1026.	1.2	78
234	Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. Neuro-Oncology, 2013, 15, 1405-1412.	1.2	53

#	Article	IF	Citations
235	Functional MHC Class II Is Upregulated in Neurofibromin-Deficient Schwann Cells. Journal of Investigative Dermatology, 2013, 133, 1372-1375.	0.7	6
236	Protein kinase CÎ² as a therapeutic target stabilizing bloodâ€“brain barrier disruption in experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 14735-14740.	7.1	43
237	A3.18â€…Synovial Fibroblasts Inhibit Inflammatory T Cell Responses through Tryptophan Metabolism. Annals of the Rheumatic Diseases, 2013, 72, A20.1-A20.	0.9	0
238	Abstract LB-80: ATRX loss refines the classification of anaplastic glioma and is a favorable prognostic marker.. , 2013, , .		1
239	The aryl hydrocarbon receptor in tumor immunity. OncoImmunology, 2012, 1, 396-397.	4.6	22
240	Shaping the glioma immune microenvironment through tryptophan metabolism. CNS Oncology, 2012, 1, 99-106.	3.0	26
241	Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncology, The, 2012, 13, 707-715.	10.7	980
242	Costimulatory Protein 4IgB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness. Clinical Cancer Research, 2012, 18, 105-117.	7.0	126
243	The aryl hydrocarbon receptor as a promoter of malignant glioma. Cell Cycle, 2012, 11, 643-644.	2.6	4
244	Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion. Cancer Research, 2012, 72, 5435-5440.	0.9	591
245	Bloodâ€“brain barrier and brain edema. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 104, 53-62.	1.8	9
246	Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase. PLoS ONE, 2012, 7, e47663.	2.5	42
247	Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro-Oncology, 2011, 13, 566-579.	1.2	121
248	An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature, 2011, 478, 197-203.	27.8	1,514
249	Geriatric neuro-oncology. Current Opinion in Neurology, 2011, 24, 599-604.	3.6	25
250	Suppression of human CD4+ T cell activation by 3,4-dimethoxycinnamonyl-anthranilic acid (tranilast) is mediated by CXCL9 and CXCL10. Biochemical Pharmacology, 2011, 82, 632-641.	4.4	41
251	Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. Acta Neuropathologica, 2011, 122, 353-365.	7.7	71
252	Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma. BMC Cancer, 2011, 11, 127.	2.6	30

#	Article	IF	Citations
253	Bevacizumab does not increase the risk of remote relapse in malignant glioma. Annals of Neurology, 2011, 69, 586-592.	5.3	71
254	Abstract LB-382: Inhibition of CD95 signalling by APG-101 enhances efficacy of radiotherapy (RT) and reduces RT-induced tumor satellite formation. , 2011, , .		1
255	The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells. PLoS ONE, 2011, 6, e19823.	2.5	126
256	Defective p53 antiangiogenic signaling in glioblastoma. Neuro-Oncology, 2010, 12, 894-907.	1.2	14
257	Mouse Mesenchymal Stem Cells Suppress Antigen-Specific TH Cell Immunity Independent of Indoleamine 2,3-Dioxygenase 1 (IDO1). Stem Cells and Development, 2010, 19, 657-668.	2.1	49
258	Angiotensin II sustains brain inflammation in mice via TGF-Î². Journal of Clinical Investigation, 2010, 120, 2782-2794.	8.2	177
259	Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 14948-14953.	7.1	755
260	New (alternative) temozolomide regimens for the treatment of glioma. Neuro-Oncology, 2009, 11, 69-79.	1.2	142
261	Toll-Like Receptor Engagement Enhances the Immunosuppressive Properties of Human Bone Marrow-Derived Mesenchymal Stem Cells by Inducing Indoleamine-2,3-dioxygenase-1 via Interferon-Î² and Protein Kinase R Â. Stem Cells, 2009, 27, 909-919.	3.2	268
262	A novel tool to analyze MRI recurrence patterns in glioblastoma. Neuro-Oncology, 2008, 10, 1019-1024.	1.2	74
263	Nanosensor Detection of an Immunoregulatory Tryptophan Influx/Kynurenine Efflux Cycle. PLoS Biology, 2007, 5, e257.	5.6	112
264	Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma. Journal of Clinical Oncology, 2007, 25, 3357-3361.	1.6	237
265	Anti-inflammatory strategies for the treatment of multiple sclerosis â€“ tryptophan catabolites may hold the key. Drug Discovery Today: Therapeutic Strategies, 2006, 3, 401-408.	0.5	7
266	Multiple sclerosis: trapped in deadly glue. Nature Medicine, 2005, 11, 252-253.	30.7	69
267	A Suppressive Oligodeoxynucleotide Enhances the Efficacy of Myelin Cocktail/IL-4-Tolerizing DNA Vaccination and Treats Autoimmune Disease. Journal of Immunology, 2005, 175, 6226-6234.	0.8	56
268	Treatment of Autoimmune Neuroinflammation with a Synthetic Tryptophan Metabolite. Science, 2005, 310, 850-855.	12.6	391
269	SD-208, a Novel Transforming Growth Factor Î² Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo. Cancer Research, 2004, 64, 7954-7961.	0.9	380
270	Involvement of protein kinase CÎ´ and extracellular signal-regulated kinase-2 in the suppression of microglial inducible nitric oxide synthase expression by N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast). Biochemical Pharmacology, 2003, 66, 1263-1270.	4.4	27

#	Article	IF	Citations
271	Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Annals of Neurology, 2003, 54, 388-392.	5.3	226
272	Ezrin-Dependent Promotion of Glioma Cell Clonogenicity, Motility, and Invasion Mediated by BCL-2 and Transforming Growth Factor-Î²2. Journal of Neuroscience, 2001, 21, 3360-3368.	3.6	85
273	Malignant glioma biology: Role for TGF-? in growth, motility, angiogenesis, and immune escape. Microscopy Research and Technique, 2001, 52, 401-410.	2.2	224
274	N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-? release and reduces migration and invasiveness of human malignant glioma cells. International Journal of Cancer, 2001, 93, 53-61.	5.1	84
275	Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. Journal of Neuro-Oncology, 2001, 53, 177-185.	2.9	231
276	N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon-Î³ (IFN-Î³). British Journal of Pharmacology, 2001, 134, 1279-1284.	5.4	20
277	Processing of Immunosuppressive Pro-TGF-Î²1,2 by Human Glioblastoma Cells Involves Cytoplasmic and Secreted Furin-Like Proteases. Journal of Immunology, 2001, 166, 7238-7243.	0.8	97
278	Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene, 2000, 19, 4210-4220.	5.9	159
279	Comprehensive Allelotype and Genetic Analysis of 466 Human Nervous System Tumors. Journal of Neuropathology and Experimental Neurology, 2000, 59, 544-558.	1.7	137
280	Transforming Growth Factors Î²1 (TGF-Î²1) and TGF-Î²2 Promote Glioma Cell Migration via Up-Regulation of Î±VÎ²3 Integrin Expression. Biochemical and Biophysical Research Communications, 2000, 268, 607-611.	2.1	130
281	A Novel Splice Site Associated Polymorphism in the Tuberous Sclerosis 2 (TSC2) Gene May Predispose to the Development of Sporadic Gangliogliomas. Journal of Neuropathology and Experimental Neurology, 1997, 56, 806-810.	1.7	29